Date of Decision: October 4, 2024
Service Center: Texas Service Center
Form Type: Form I-140
Case Type: EB-1 Extraordinary Ability
Petitioner Information
Profession: Vaccine Industry Executive
Field: Vaccine Business Strategy and Development
Nationality: Not specified in the document
Summary of Decision
Initial Decision: Denied
Appeal Outcome: Withdrawn and remanded for further determination
Evidentiary Criteria Analysis
The petitioner sought to meet at least three of the ten regulatory criteria under 8 C.F.R. § 204.5(h)(3). Upon review, the Administrative Appeals Office (AAO) determined that the petitioner met two criteria and required further evaluation for one additional criterion.
Criteria Met:
- Performance in a Leading or Critical Role for Distinguished Organizations:
- The petitioner demonstrated leadership roles, including serving as Senior Vice President for vaccine business development and later as Chief Business Officer of a vaccine company.
- High Salary or Significantly High Remuneration:
- The petitioner provided evidence of earning a significantly high salary, corroborated by compensation reports in the vaccine industry.
Criteria Requiring Further Evaluation:
- Original Contributions of Major Significance:
- The petitioner provided evidence of negotiating critical vaccine licensing agreements and leading pandemic preparedness efforts. Letters of support from prominent figures, such as Dr. Anthony Fauci, emphasized the petitioner’s contributions. The AAO remanded this criterion for reconsideration, as the Director evaluated it under scientific standards instead of business-related contributions.
Key Points from the Decision
Leadership Evidence:
- The petitioner held leading roles in organizations with distinguished reputations in the vaccine industry, substantiated by media coverage and support letters.
Original Contributions:
- Contributions included negotiating pandemic preparedness agreements and licensing vaccines. While these were significant, the Director’s review applied scientific benchmarks, which were deemed inappropriate given the petitioner’s focus on business contributions.
Published Material and Membership Evidence:
- Articles mentioning the petitioner focused on organizational achievements rather than his individual contributions, failing to meet the published material criterion. Membership in industry groups was not proven to require outstanding achievements.
Final Merits Determination:
- The AAO instructed the Director to assess the petitioner’s evidence under the appropriate business context and conduct a final merits determination if the original contributions criterion is satisfied.
Supporting Documentation
Leadership Evidence: Senior Vice President and Chief Business Officer roles in distinguished organizations.
Compensation Evidence: Reports substantiating significantly high earnings in the vaccine industry.
Contribution Evidence: Negotiation of critical agreements and pandemic preparedness initiatives, supported by letters from prominent figures.
Conclusion
Final Determination: The Director’s decision was withdrawn, and the matter was remanded for further analysis and decision-making.
Reasoning:
The petitioner met two regulatory criteria under 8 C.F.R. § 204.5(h)(3). Further evaluation of original contributions is required to determine eligibility for EB-1 classification.
